PDS Biotechnology Welcomes Stephan Toutain as New COO

TipRanks24minutes ago

PDS Biotech To Event To Discuss Positive, Updated Data From Phase 2 VERSATILE-002 Clinical Trial With Versamune HPV In Combination With KEYTRUDA In Recurrent Or Metastatic Head And Neck Cancer

Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Needs in Advanced Head and Neck Cancer and planned Triple Combination Trial

BenzingaApr 23 20:01

PDS Biotechnology Corporation's (NASDAQ:PDSB) Market Cap Dropped US$1.5m Last Week; Individual Investors Who Hold 59% Were Hit as Were Institutions

Yahoo FinanceMar 30 20:35

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 28 22:15

Noble Financial Sticks to Its Buy Rating for PDS Biotechnology (PDSB)

TipRanksMar 28 20:25

B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating

B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating.

MT NewswiresMar 28 19:57